Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 9/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4543952 | 0.77 | HRH4 (0.57) | HRH4SSTR5 | |
| SCHEMBL3950574 | 0.76 | HRH4 (0.46) | HRH4SSTR5SSTR2KCNH2 | |
| SCHEMBL4537534 | 0.76 | HRH4 (0.50) | HRH4SSTR5 | |
| SCHEMBL2913118 | 0.74 | HRH4 (0.83) | HRH4SSTR5TNKSPARP1TNKS2 | |
| SCHEMBL16266191 | 0.73 | HRH4 (0.59) | HRH4CARM1SSTR2KCNH2 | |
| SCHEMBL2911883 | 0.70 | HRH4 (0.41) | HRH4SSTR2KCNH2 | |
| SCHEMBL4087266 | 0.66 | HRH4 (0.44) | HRH4PARP1 | |
| SCHEMBL2913640 | 0.66 | HRH4 (1.00) | HRH4SSTR5TNKSPARP1TNKS2 | |
| SCHEMBL2912375 | 0.66 | HRH4 (0.82) | HRH4CARM1SSTR2KCNH2 | |
| SCHEMBL2906607 | 0.65 | HRH4 (0.83) | HRH4SSTR5TNKSPARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507737-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-24 | — | — | US | disclosed |
| US-20070244126-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244126-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | HRH4 1/4885SSTR5 616/4885TNKS 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.